A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients . Clinics. 2016;71(10):586-592. doi:10.6061/clinics/2016(10)06